Press Releases

Date Title  
Toggle Summary Natera and BGI Genomics Announce $50M Partnership to Commercialize Signatera Oncology Test in China and to Develop Reproductive Health Tests in Select Markets on BGI's DNBseq™ Technology Platform
Partnership marks significant milestone for Natera in monetizing its Signatera MRD test and for BGI Genomics a strong endorsement of its DNBseq™ technology platform by a leader in cell-free DNA genetic testing SAN CARLOS, Calif. and SHENZHEN, China , March 11, 2019 /PRNewswire/ --   Natera, Inc.
Toggle Summary /C O R R E C T I O N -- Natera, Inc./
In the news release, Natera, Inc. Announces Fourth Quarter and Fiscal 2018 Earnings Conference Call, issued 05-Mar-2019 by Natera, Inc. over PR Newswire, we are advised by the company that the first paragraph, last sentence, as well as the 'Earnings Conference Call Information" section should read
Toggle Summary Natera, Inc. Announces Fourth Quarter and Fiscal 2018 Earnings Conference Call
Natera Also to Present at 39th Annual Cowen Healthcare Conference SAN CARLOS, Calif. , March 5, 2019 /PRNewswire/ --   Natera, Inc.  (NASDAQ: NTRA), a leader in cell-free DNA, today announced that it will release results for its fourth quarter and year ended December 31, 2018 , after the market
Toggle Summary Natera Announces Publication of Analytical Validation Study Demonstrating Superior Precision of Its Kidney Transplant Rejection Assay
Core Technology Delivers Superior Analytical Performance, Underpins Outstanding Clinical Performance SAN CARLOS, Calif. , Feb. 22, 2019 /PRNewswire/ --   Natera, Inc.  (NASDAQ: NTRA), a leader in cell-free DNA, today announced analytical validation study results to be published online in the
Toggle Summary Natera Presents Outcomes Data at SMFM Annual Meeting Showing Strong Clinical Performance of Its SNP-Based Non-Invasive Prenatal Test
Study Shows High Positive Predictive Values in Detecting Common Chromosomal Aneuploidies in All Women, Including Women Under 35 Years of Age SAN CARLOS, Calif. , Feb. 19, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in cell-free DNA testing, presented data at the Society for
Toggle Summary Natera Announces Agreement with One Lambda to Co-Distribute Its Kidney Transplant Rejection Test
Agreement Enhances Commercial Presence in Organ Transplant Centers SAN CARLOS, Calif. , Feb. 1, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, today announced a partnership with Thermo Fisher Scientific's One
Toggle Summary Natera Announces Publication of Kidney Transplant Validation Study, Demonstrating Superior Data in Detection of Clinical and Subclinical Rejection
Represents Successful Achievement of All 2018 Commercialization Milestones, on Path to 2019 Launch SAN CARLOS, Calif. , Jan. 7, 2019 /PRNewswire/ --  Natera, Inc. (NASDAQ: NTRA), a leader in cell-free DNA, today announced clinical validation study results published in the Journal of Clinical
Toggle Summary Natera To Webcast Live Presentation at the 37th Annual J.P. Morgan Healthcare Conference
SAN CARLOS, Calif. , Jan. 4, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, today announced that it will webcast a live presentation at the 37 th Annual J.P. Morgan Healthcare Conference at the Westin St.
Toggle Summary Natera Obtains Z-Codes for Signatera MRD and Treatment Monitoring Test in Oncology
Represents Key Reimbursement Milestone In Line with Planned Clinical Launch SAN CARLOS, Calif. , Jan. 4, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a global leader in non-invasive genetic testing and cell-free DNA, today announced the assignment of two Z-codes for the company's Signatera™
Toggle Summary Natera Appoints Steve Chapman CEO and Robert Schueren COO; Matthew Rabinowitz Moves to Executive Chairman
Proven Commercial Execution Selected for CEO Role; Seasoned Operational Expertise Selected for COO Role SAN CARLOS, Calif. , Jan. 2, 2019 /PRNewswire/ --  Natera, Inc.  (NASDAQ: NTRA), a leader in non-invasive genetic testing and the analysis of cell-free DNA, has announced the appointment of Steve

Footer disclaimer

Footer disclaimer

© Natera 2019. All Rights Reserved. The tests described on this site were developed by Natera, Inc. a laboratory certified under the Clinical Laboratory Improvement Amendments (CLIA). The tests have not been cleared or approved by the U.S. Food and Drug Administration (FDA). Although FDA does not currently clear or approve laboratory-developed tests in the U.S., certification of the laboratory is required under CLIA to ensure the quality and validity of the tests.